Basilea Pharmaceutica Ltd. has entered into a collaboration with Roche to explore a combination of Basilea’s derazantinib and Roche‘s PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq) in patients with urothelial cancer. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study mid-2019. Marc Engelhardt, chief medical officer, Basilea, “We are very pleased with this collaboration. This is an important study as it explores a novel targeted ...